Alendronate for the treatment of osteoporosis in men

Bibliography

• Melton LJ 3rd. The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 2001;69:179-81
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505S-511S
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3-7
   PubMed Web of Science ®Google Scholar
• Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-9
   PubMed Web of Science ®Google Scholar
• Melton LJ 3rd, Atkinson EJ, O'Connor MK, et al. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-23
   PubMed Web of Science ®Google Scholar
• Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998;27:349-67
   PubMed Web of Science ®Google Scholar
• Lunt M, Felsenberg D, Reeve J, et al. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 1997;12:1883-94
   PubMed Web of Science ®Google Scholar
• Davies KM, Stegman MR, Heaney RP, Recker RR. Prevalence and severity of vertebral fracture: the Saunders County Bone Quality Study. Osteoporos Int 1996;6:160-5
   PubMed Web of Science ®Google Scholar
• Jones G, White C, Nguyen T, et al. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 1996;6:233-9
   PubMed Web of Science ®Google Scholar
• Burger H, Van Daele PL, Grashuis K, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997;12:152-7
   PubMed Web of Science ®Google Scholar
• O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-8
   PubMed Web of Science ®Google Scholar
• Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 2000;11:680-7
   PubMed Web of Science ®Google Scholar
• Myers AH, Robinson EG, Van Natta ML, et al. Hip fractures among the elderly: factors associated with in-hospital mortality. Am J Epidemiol 1991;134:1128-37
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
   PubMed Web of Science ®Google Scholar
• Seeman E. Unresolved issues in osteoporosis in men. Rev Endocr Metab Disord 2001;2:45-64
   PubMedGoogle Scholar
• Elliott JR, Gilchrist NL, Wells JE, et al. Effects of age and sex on bone density at the hip and spine in a normal Caucasian New Zealand population. NZ Med J 1990;103:33-6
   PubMed Web of Science ®Google Scholar
• Slosman DO, Rizzoli R, Pichard C, et al. Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int 1994;4:185-90
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Oviatt SK, McClung MR, et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990;112:29-34
   PubMed Web of Science ®Google Scholar
• Jones G, Nguyen T, Sambrook P, et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994;309:691-5
   PubMed Web of Science ®Google Scholar
• Mullender MG, Tan SD, Vico L, et al. Differences in osteocyte density and bone histomorphometry between men and women and between healthy and osteoporotic subjects. Calcif Tissue Int 2005;77:291-6
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16:87-116
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton LJ 3rd, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-74
   PubMed Web of Science ®Google Scholar
• Bobba R, Adachi JD. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clin Interv Aging 2007;2:275-82
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005;16:510-6
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1 – 34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
   PubMed Web of Science ®Google Scholar
• Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006;26:427-31
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Thompson DE, Black DM, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005;20:971-6
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
   PubMed Web of Science ®Google Scholar
• Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
   PubMed Web of Science ®Google Scholar
• Lenart B, Neviaser A, Peterson MG, et al. Low energy femoral diaphyseal fractures associated with alendronate use. J Bone Miner Res 2007;22
   Google Scholar
• Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16
   PubMed Web of Science ®Google Scholar
• Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36:315-28
   PubMed Web of Science ®Google Scholar
• Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-8
   PubMed Web of Science ®Google Scholar
• Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
   PubMed Web of Science ®Google Scholar
• Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10
   PubMed Web of Science ®Google Scholar
• Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5
   PubMed Web of Science ®Google Scholar
• Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110-3
   PubMed Web of Science ®Google Scholar
• Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 2000;11:98-101
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Cepollaro C, Montagnani A, et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 2003;73:133-9
   PubMed Web of Science ®Google Scholar
• Olszynski WP, Davison KS, Ioannidis G, et al. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. Osteoporos Int 2006;17:217-24
   PubMed Web of Science ®Google Scholar
• Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005;6:39
   PubMed Web of Science ®Google Scholar
• Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87
   PubMed Web of Science ®Google Scholar
• van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79:129-37
   PubMed Web of Science ®Google Scholar
• Cruse LM, Valeriano J, Vasey FB, Carter JD. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 2006;12:221-5
   PubMed Web of Science ®Google Scholar
• Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002;17:1512-26
   PubMed Web of Science ®Google Scholar
• Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416-24
   PubMed Web of Science ®Google Scholar
• El-Agroudy AE, El-Husseini AA, El-Sayed M, et al. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 2005;67:2039-45
   PubMed Web of Science ®Google Scholar
• Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001;16:2111-7
   PubMed Web of Science ®Google Scholar
• Koc M, Tuglular S, Arikan H, et al. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 2002;34:2111-3
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;61:382-5
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004;5:269-77
   PubMed Web of Science ®Google Scholar
• Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005;38:426-31
   PubMed Web of Science ®Google Scholar
• Shimon I, Eshed V, Doolman R, et al. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int 2005;16:1591-6
   PubMed Web of Science ®Google Scholar
• Marshall JK, Rainsford KD, James C, Hunt RH. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 2000;14:1451-7
   PubMed Web of Science ®Google Scholar
• Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95:3112-7
   PubMed Web of Science ®Google Scholar
• Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000;22:1433-42
   PubMed Web of Science ®Google Scholar
• Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 2001;13:347-54
   PubMedGoogle Scholar
• Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-25
   PubMed Web of Science ®Google Scholar
• Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002;77:1044-52
   PubMed Web of Science ®Google Scholar
• Eisman JA, Rizzoli R, Roman-Ivorra J, et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2004;20:699-705
   PubMed Web of Science ®Google Scholar
• Cryer B, Miller P, Petruschke RA, et al. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther 2005;21:599-607
   PubMed Web of Science ®Google Scholar
• Cosman F, Wermers RA, Recknor C, et al. Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. J Bone Miner Res 2007;22
   Google Scholar
• Epstein S, Cryer B, Ragi S, et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003;19:781-9
   PubMed Web of Science ®Google Scholar